Preclinical Evaluation of Repurposed Antimalarial Artemisinins for the Treatment of Malignant Peripheral Nerve Sheath Tumors
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146628 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Heather M Duensing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27268, USA. Hauptthemen laut MEDLINE: Artemisinins, Antimalarials, Drug Repositioning, Nerve Sheath Neoplasms. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: North Carolina Biotechnology Center, High Point University Natural Science Fellows Supply Grant, High Point University Natural Science Fellows.
Abstract (Originalsprache)
Malignant peripheral nerve sheath tumors (MPNSTs) are a rare type of soft tissue sarcoma associated with poor prognoses. The standard of care for non-resectable tumors consists of surgical excision followed by radiation and chemotherapy. MPNSTs are most common in patients with neurofibromatosis type 1 but can also occur sporadically. Regardless of origin, MPNSTs most often rely on signaling pathways that increase basal oxidative stress. This provides the basis for developing therapeutics with mechanisms that can potentiate oxidative stress to selectively eradicate tumor cells at doses that are tolerable for normal cells. Artemisinin derivatives are a mainstay of malaria therapy worldwide, with a well-established safety profile. Artemisinin’s antimalarial effects are due to an endoperoxide bridge in its chemical structure that induces oxidative stress. We found that artesunate (ARS) and metabolite dihydroartemisinin (DHA) are selectively cytotoxic to MPNST cells relative to normal Schwann cells with the endoperoxide bridge required for activity. Mechanistically, DHA induced oxidative stress, lipid peroxidation, and DHA-mediated cytotoxicity could be prevented with co-administration of the antioxidant N-acetyl-cysteine. Furthermore, we found that DHA was able to selectively remove MPNST from co-culture with normal Schwann cells. These data supports the further development of artemisinins for the clinical management of MPNST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27268, USA.
ORCID-Profile: Nickalus C Smith, Cale D Fahrenholtz
Förderung
- North Carolina Biotechnology Center
- High Point University Natural Science Fellows Supply Grant
- High Point University Natural Science Fellows
Zitieren
APA
Duensing, H. M., Dixon, J. M., Hunter, O. R., Graves, N. C., Smith, N. C., Tomes, A. J., & Fahrenholtz, C. D. (2025). Preclinical Evaluation of Repurposed Antimalarial Artemisinins for the Treatment of Malignant Peripheral Nerve Sheath Tumors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146628
Vancouver
Duensing HM, Dixon JM, Hunter OR, Graves NC, Smith NC, Tomes AJ, et al. Preclinical Evaluation of Repurposed Antimalarial Artemisinins for the Treatment of Malignant Peripheral Nerve Sheath Tumors. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146628
BibTeX
@article{Duensing2025,
author = {Duensing, Heather M and Dixon, Jalen M and Hunter, Owen R and Graves, Nicolina C and Smith, Nickalus C and Tomes, Andersen J and Fahrenholtz, Cale D},
title = {Preclinical Evaluation of Repurposed Antimalarial Artemisinins for the Treatment of Malignant Peripheral Nerve Sheath Tumors},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146628}
}
EUVIMED